Homo sapiens
Ontology highlight
ABSTRACT:
PROVIDER: PRJNA111659 | ENA |
REPOSITORIES: ENA
Similar Datasets
Project description:Expression data from Tamoxifen resistant Breast Cancer Cell lines
| PRJNA128001 | ENA
Project description:Gene expression analysis in tamoxifen resistant ER+ breast cancer cell lines
| PRJNA281201 | ENA
Project description:Exome-sequencing of tamoxifen-resistant and -sensitive breast cancer cell lines.
| PRJNA264355 | ENA
Project description:RNA-sequencing of tamoxifen-resistant and -sensitive breast cancer cell lines.
| PRJNA377829 | ENA
Project description:genomic, transcriptomic and epigenomic studes of the human breast cancer tamoxifen-resistant cell lines
| PRJNA237356 | ENA
Project description:microRNA expression profiles in Aromatase Inhibitor-Resistant, Tamoxifen-Resistant and LTED breast cancer cell lines.
| PRJNA118399 | ENA
Project description:MicroRNA expression profiling of tamoxifen sensitive and resistant ER+ breast cancer cell lines
| PRJNA243262 | ENA
Project description:We report mRNA profiles of human breast cancer cell lines, MCF7 parental, and MCF7-derived tamoxifen resistant cell lines MCF7-TR1 and MCF7-TR2.
2023-10-25 | GSE241654 | GEO
Project description:Tamoxifen is an effective anti-estrogen treatment for patients with estrogen receptor-positive (ER+) breast cancer. However, about 30% of such patients receiving tamoxifen as an adjuvant therapy experience recurrence within 15 years, and most patients with advanced disease eventually develop resistance to tamoxifen. To elucidate the underlying molecular mechanisms of tamoxifen resistance, we performed a systematic analysis of miRNA-mediated gene regulation in three clinically-relevant tamoxifen-resistant human breast cancer cell lines (TamRs) compared to their parental tamoxifen-sensitive MCF-7/S0.5 cell line. Alterations in the expression of 131 miRNAs in tamoxifen-resistant vs. parental cell lines were identified, 22 of which were common to all TamRs using both sequencing and LNA-based quantitative PCR technologies. ER+ and tamoxifen sensitive breast cancer cell line (MCF-7/S0.5) and its derived tamoxifen resistant clones: TAMR-1, TAMR-4 and TAMR-8 were miRNA expression profiled in triplicates of each using Exiqon's miRCURY LNA based microRNA Ready-to-use PCR, Human panel I+II, V2.R (Exiqon, product number 203608).
2015-08-01 | E-GEOD-56411 | biostudies-arrayexpress
Project description:Tamoxifen is an effective anti-estrogen treatment for patients with estrogen receptor-positive (ER+) breast cancer. However, about 30% of such patients receiving tamoxifen as an adjuvant therapy experience recurrence within 15 years, and most patients with advanced disease eventually develop resistance to tamoxifen. To elucidate the underlying molecular mechanisms of tamoxifen resistance, we performed a systematic analysis of miRNA-mediated gene regulation in three clinically-relevant tamoxifen-resistant human breast cancer cell lines (TamRs) compared to their parental tamoxifen-sensitive MCF-7/S0.5 cell line. Alterations in the expression of 131 miRNAs in tamoxifen-resistant vs. parental cell lines were identified, 22 of which were common to all TamRs using both sequencing and LNA-based quantitative PCR technologies.
2015-08-01 | GSE56411 | GEO